Latest Breaking News On - Pieris pharmaceuticals - Page 7 : comparemela.com

Investment Analysts New Coverage for February 25th (AMPE, APDN, BKCC, BKSC, BLIN, BYFC, CASI, CMCT, CPE, CPRI)

Investment Analysts New Coverage for February 25th (AMPE, APDN, BKCC, BKSC, BLIN, BYFC, CASI, CMCT, CPE, CPRI)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesSouth carolinaNustar energyPieris pharmaceuticalsAmpio pharmaceuticalsCodorus valley bancorpCallon petroleumAmpio pharmaceuticals incCreative media community trust coNews ratings for ampio pharmaceuticals inc dailyInvestment analystBlackrock capital investmentBridgeline digitalBroadway financialCreative mediaCommunity trust

Investment Analysts New Coverage for February 25th (AMPE, APDN, BKCC, BKSC, BLIN, BYFC, CASI, CMCT, CPE, CPRI)

Investment Analysts’ new coverage for Sunday, February 25th: StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE). The firm issued a sell rating on the stock. StockNews.com assumed coverage on shares of Applied DNA Sciences (NASDAQ:APDN). The firm issued a hold rating on the stock. StockNews.com initiated coverage on shares of BlackRock Capital Investment (NASDAQ:BKCC). […]

South carolinaUnited statesPieris pharmaceuticalsNustar energyCodorus valley bancorpCallon petroleumAmpio pharmaceuticalsAmpio pharmaceuticals incNews ratings for ampio pharmaceuticals inc dailyCreative media community trust coInvestment analystBlackrock capital investmentBridgeline digitalBroadway financialCreative mediaCommunity trust

Pieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews com

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a report published on Saturday. The firm issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Trading Up 8.3 % Shares of PIRS opened at $0.17 on Friday. The company’s fifty day simple moving average is $0.17 and its 200-day […]

Institutional trading of pieris pharmaceuticalsNews ratings for pieris pharmaceuticals dailyPieris pharmaceuticals incPieris pharmaceuticals tradingTopco ltdHsbc holdingsOppenheimer coPieris pharmaceuticalsMirabella financial servicesTower research capitalFree reportFinancial servicesResearch capitalGet free reportPieris pharmaceuticals dailyNasdaq pirs

A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tumors

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

South koreaUniversity of washingtonUnited statesMegan alhadeffJavlem overexpressionThanh buiTiffany tamChemother pharmacolKanwal pratap singh raghavSalvatore sienaVan cutsemAtsuo takashimaDaiichi sankyoFred hutchinson cancer centerAmerican society for clinical pathologyAmerican society of clinical oncology

StockNews com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Price Performance NASDAQ:PIRS opened at $0.16 on Wednesday. The business’s 50-day moving average is $0.18 and its two-hundred day moving average […]

Pieris pharmaceuticalsNews ratings for pieris pharmaceuticals dailyPieris pharmaceuticals incPieris pharmaceuticals company profileTopco ltdMirabella financial servicesInstitutional trading of pieris pharmaceuticalsHsbc holdingsTower research capitalOppenheimer coPieris pharmaceuticals price performanceFree reportGet free reportFinancial servicesResearch capitalPieris pharmaceuticals daily